<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Vernakalant is a new antiarrhythmic drug that acts selectively in the atrium, targeting atrial specific channels: the Kv1.5 channel which carries IK(ur), and the Kir3.1/3.4 channel which carries IK(<z:chebi fb="93" ids="22614">Ach</z:chebi>) </plain></SENT>
<SENT sid="1" pm="."><plain>Vernakalant can also work to block Ito, late Ina, with minor blockade of IKr currents </plain></SENT>
<SENT sid="2" pm="."><plain>Vernakalant is available in both intravenous and oral forms </plain></SENT>
<SENT sid="3" pm="."><plain>In phase II and III trials, intravenous vernakalant has been shown to be effective in terminating <z:hpo ids='HP_0011009'>acute onset</z:hpo> <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> whose duration is &gt;3 hours and &lt;7 days (âˆ¼50% efficiency vs. 10% for placebo) </plain></SENT>
<SENT sid="4" pm="."><plain>It does not appear to be effective for <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> whose duration is &gt;7 days, nor does it appear to be effective for <z:hpo ids='HP_0004749'>atrial flutter</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Studies with oral vernakalant have been designed to evaluate its efficacy and safety in the prevention of <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> recurrence </plain></SENT>
<SENT sid="6" pm="."><plain>Studies to date have shown that 51% of patients were able to maintain sinus rhythm after 90 days of using oral vernakalant 50 mg/kg twice daily compared with 37% of patients receiving placebo </plain></SENT>
<SENT sid="7" pm="."><plain>Vernakalant appears to be a safe drug to use, with the most common side-effects being dysgeusia, sneezing, <z:hpo ids='HP_0003401'>paresthesias</z:hpo>, <z:hpo ids='HP_0002018'>nausea</z:hpo>, and <z:hpo ids='HP_0002615'>hypotension</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>In the clinical trials, there were minimal drug-induced <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> observed </plain></SENT>
</text></document>